🔴 Neurosense Therapeutics is trading 10.97% down today; no specific catalyst confirmed

Neurosense Therapeutics is trading at $0.34, down -10.97%, with no specific catalyst confirmed.

• No credible company-specific announcement dated August 19, 2026, was found to explain the decline.
• Recent coverage cites Phase 3 funding delays, Nasdaq compliance concerns, and a proposed 1-for-4 to 1-for-40 reverse split; these items predate August 19.
• The broader biotech sector is reportedly rising, so sector strength does not explain the decline.